Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccines 98

Vaccines Immunity Immunization Communication 98

Pharmaceutical Technology

DECEMBER 21, 2022

This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.

Vaccines 140

Vaccines Communication 140

Pharmaceutical Technology

APRIL 6, 2023

Moderna has announced that its cancer vaccine mRNA-4157/V940 along with Keytruda secured the European Medicines Agency (EMA) Priority Medicines (PRIME) scheme designation for the adjuvant treatment of high-risk stage III/IV melanoma patients after complete resection.

Vaccines 98

Vaccines Labelling Immunity Immunization 98

Pharmaceutical Technology

JANUARY 31, 2023

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Moderna ’s investigational mRNA vaccine candidate, mRNA-1345, for respiratory syncytial virus (RSV) in adult patients. The investigational mRNA-1345 vaccine uses the same lipid nanoparticles (LNPs) that are also used in the Moderna Covid-19 vaccines.

Vaccines 72

Vaccines Communication 72

Pharmaceutical Technology

DECEMBER 18, 2022

The 0.25mL dose of the booster vaccine could potentially be used in the European Union (EU) following authorisation in these children a minimum of three months following a previous Covid-19 vaccination. 1273.214, a bivalent Omicron-targeting Covid-19 vaccine of the company. 5), mRNA-1273. By Cytiva Thematic.

Vaccines 121

Vaccines Communication 121

pharmaphorum

AUGUST 25, 2022

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science officer respectively of Transgene, to discuss cancer vaccines in general and Transgene’s recent work in the space in particular. . Tune in to learn more. . You can listen to episode 58 of the? Podbean. .

Vaccines 52

Vaccines Immunization Immunity 52

pharmaphorum

DECEMBER 8, 2022

Novavax’s COVID-19 vaccine now in hand and licensed around the globe, Trizzino discussed the need to nurture its EU relationships and investments during the company’s current commercialisation drive. The conversation concludes on how tangible innovation and data speaks for itself.

Vaccines 98

Vaccines 98

Pharmaceutical Technology

NOVEMBER 30, 2022

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments. By Cytiva Thematic.

Vaccines 59

Vaccines Communication 59

pharmaphorum

MARCH 2, 2021

The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. Download the Full Event Guide here. Overcome immunogenicity challenges and design safe and efficacious vaccine formulations. Register online here to take part.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 64

Pharmaceutical Technology

DECEMBER 5, 2022

With the establishment of this Translational Science Hub, Queensland is set to become an international messenger ribonucleic acid (mRNA) vaccine hub. With an initial focus on enchaining mRNA technology and developing a vaccine for Chlamydia, the research at the hub is anticipated to commence in the first quarter of next year.

Vaccines 98

Vaccines Communication Immunity Immunization 98

Pharmaceutical Technology

MARCH 23, 2023

China’s National Medical Products Administration (NMPA) has granted emergency use authorisation (EUA) for CSPC Pharmaceutical Group’s messenger RNA (mRNA) vaccine, SYS6006, to treat Covid-19. With this regulatory approval, CSPC Pharmaceutical is claimed to be the first company to receive approval for providing an mRNA vaccine in the country.

Vaccines 52

Vaccines Communication 52

Putting Patients First Blog

JULY 7, 2023

The NHC Releases Research Brief and Infographic on COVID-19 Vaccine Technology and Hesitancy July 7, 2023 By: Lillian L.Q. Witting, MPH, Coordinator, Research, Education, and Programs Vaccinations are a major accomplishment of the 20th century. Though the COVID-19 pandemic has taken a turn, it is still present in our everyday lives.

Vaccines 52

Vaccines Immunity Immunization 52

Eye on FDA

MARCH 31, 2021

This week New York became the first state to make available a means for mobile digital confirmation that an individual has been vaccinated for COVID-19. Israel – much further along in its vaccination process – has implemented their version called “Green Pass” and France is set to launch one soon.

Vaccines 98

Vaccines Immunization Immunity Hospitals 98

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

Vaccines 98

Vaccines Communication 98

Drug Channels

FEBRUARY 22, 2022

Those who preorder will receive a download link before March 15. CLICK HERE to download a free pre-publication overview. Download a free report overview for more details. We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2022 edition at special discounted prices.

Specialty Pharmacies 96

Specialty Pharmacies Drug Pricing Biosimilars Vaccines 96

Digital Pharmacist

JANUARY 16, 2023

National Influenza Vaccination Week: December 6-12. Cervical Health Awareness Month | S hare downloadable content from the NCCC and advocate for HPV vaccinations. World Immunization Week | Post a flyer and share a list on social media of your vaccination offerings. . National Diabetes Month. COPD Awareness Month.

Immunization 98

Immunization Immunity Vaccines Diabetes 98

pharmaphorum

OCTOBER 13, 2022

In this episode of the pharmaphorum podcast series, Dr Paul Tunnah chats with Jeff Baxter, CEO of VBI Vaccines and Lee Taurman, executive vice president full service commercial at Syneos Health. Jeff Baxter – President and CEO, VBI Vaccines. About the interviewees. Whitman School of Management at Syracuse University.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

MAY 12, 2023

BioNTech has ended its research collaboration with Matinas after its oral mRNA vaccine failed to demonstrate preclinical activity. Whilst BioNTech has shelved its oral mRNA vaccine project, shares were up this week following promising early results of a personalised mRNA vaccine for pancreatic cancer.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

NOVEMBER 15, 2022

When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. This also has clear advantages in healthcare settings, particularly when it comes to vaccines. In general, a prefilled syringe is clearly preferred for vaccines.”. A new challenge .

Packaging 52

Packaging Vaccines Dosage Compounding 52

Pharmacy Joe

OCTOBER 14, 2020

In this episode, I’ll discuss why the quadrivalent meningococcal vaccine was used as a control for a COVID-19 vaccine. Episode 548: Why was the quadrivalent meningococcal vaccine used as a control for a COVID-19 vaccine? The delivery of this spike protein then causes the immunogenicity to the virus to develop.

Vaccines 40

Vaccines Inpatient 40

Pharmaceutical Technology

JUNE 1, 2023

A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. Another key focus area will be the creation of a framework to develop advanced nano-delivery systems.

Vaccines 97

Vaccines Drug Development 97

Pharmaceutical Technology

NOVEMBER 1, 2022

If you want to learn more about the Rankings and the range of marketing materials and options available to promote your achievement then please get in touch with us or download the Media Pack : Contact: Sundeep Makkar – Sundeep.Makkar@Verdict.co.uk. This category highlights companies that have advanced the research of vaccines.

Vaccines 91

Vaccines Drug Development 91

Pharmacy Joe

FEBRUARY 24, 2021

In this episode, I’ll discuss the CDC Recommendations if a patient develops COVID-19 before receiving the 2nd vaccine dose. Patients who get COVID-19 before their 2nd vaccine dose and are treated with a monoclonal antibody, and 2. This guidance also applies to people who get COVID-19 before getting their second dose of vaccine.

Vaccines 40

Vaccines Inpatient Immunity Immunization 40

pharmaphorum

MARCH 23, 2021

Download the event guide here. Showcasing ground-breaking advances in NK, TCR, and CAR-T cell therapies, as well as comparing durability and breadth of the response of novel T-cell directed vaccines, join this meeting to progress your understanding of this new era of infectious disease therapy.

Immunization 52

Immunization Immunity Vaccines 52

European Pharmaceutical Review

OCTOBER 3, 2024

Login or create an account to download your copy of our Issue now! Preparing for the impact of EU GMP Annex 1 on primary packaging Niamh Bissett and Dr Ana Kuschel West Pharmaceutical Services, Inc. The post <em>European Pharmaceutical Review </em> Issue 4 2024 appeared first on European Pharmaceutical Review.

Packaging 59

Packaging Vaccines 59

Pharmacy Joe

SEPTEMBER 23, 2021

In this episode, I’ll discuss a possible syndrome that might herald vaccine-induced immune thrombotic thrombocytopenia. Episode 646: Does vaccine-induced immune thrombotic thrombocytopenia have a “pre-VITT syndrome” ? All 11 patients presented with severe headache 5 to 18 days after adenovirus vector vaccination.

Immunity 40

Immunity Immunization Vaccines Inpatient 40

pharmaphorum

MAY 17, 2022

Expect exclusive data from the movers and shakers in mRNA vaccine and therapy development, 75+ world-class speakers, 5 dedicated tracks of content, and 45+ deep-dive case studies. Rituparna Das, VP – COVID Vaccines, Moderna. Pervin Anklesaria, Deputy Director, HIV Vaccines & Biologics, Bill & Melinda Gates Foundation.

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MARCH 31, 2023

The company will construct the new advanced mRNA facility, which is claimed to be Moderna’s first mRNA manufacturing facility in Africa and is expected to have the capacity to produce up to 500 million vaccine doses annually.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

SEPTEMBER 8, 2022

The information contained within the download document is designed for pharmaceutical executives, developers, research scientists and associates, regulatory solutions consultants, and any other individual involved in API biologics production in the pharmaceutical industry.

Vaccines 40

Vaccines Packaging Documentation Labelling 40

Pharmaceutical Technology

APRIL 4, 2023

Gennova Biopharmaceuticals has applied for an emergency use authorisation (EUA) from the Drug Controller General of India (DCGI) for its mRNA-based Omicron-specific Covid-19 booster vaccine. Dubbed GEMCOVAC-OM, the needle-free vaccine will be delivered intradermally with the PharmaJet Tropis Precision Delivery System (PDS).

Vaccines 59

Vaccines 59

Pharmaceutical Technology

APRIL 20, 2023

Circio aims to develop new circRNA medicines initially for cancer, then plans to expand rapidly into vaccines and gene therapy. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

Vaccines 96

Vaccines 96

Pharmaceutical Technology

SEPTEMBER 6, 2022

The download contains detailed information on the providers and their services and solutions, alongside contact details to aid your purchasing or hiring decision. The post Leading pharmaceutical logistics and pharma supply chain companies appeared first on Pharmaceutical Technology.

Pharmaceutical Manufacturing 59

Pharmaceutical Manufacturing Vaccines Documentation Hospitals 59

European Pharmaceutical Review

JUNE 28, 2024

Taly Dvorkis Fieldfisher QA/QC MICROBIOLOGY IN DEPTH FOCUS Implementing single temperature incubation Guillaume Pinon Laboratoires SERVIER Industrie Endotoxin standards: reflection and recommendation Dr Radhakrishna Tirumalai Merck Research Laboratories (MRL) Karen Zink McCullough MMI Associates, LLC Improving aseptic connections throughout the manufacturing (..)

Research Laboratories 52

Research Laboratories Vaccines Drug Development Immunity 52

Digital Pharmacist

OCTOBER 25, 2023

You can even download additional resources and graphics related to national diabetes day at this link. By encouraging routine immunizations, such as flu shots, pneumococcal, and even hepatitis vaccines, you are not only protecting your patients from these diseases but also from the complications that can accompany them.

Diabetes 105

Diabetes Medication Therapy Management (MTM) Immunity Immunization 105

pharmaphorum

AUGUST 16, 2022

Given the rapid developments in the field and the success of Pfizer / BioNTech’s mRNA vaccine, lipid nanoparticles have finally reached an inflection point.?With to exploit the use of LNP beyond mRNA vaccines. . Why don’t you download the full agenda to find out more? The past 24 months saw a wave? of innovations?to

Vaccines 52

Vaccines 52

pharmaphorum

MAY 28, 2021

He discussed how COVID vaccines have raised the profile of the pharma industry in the perception of the general public. The sector as a whole performed very well, according to Meade, with companies who have advanced their vaccines performing particularly well.

Vaccines 52

Vaccines 52